Erbitux is a monoclonal antibody. It is seldom used as a monotherapy since it does not directly kill malignant cells. It blocks a protein messenger that tells the malignant cells to duplicate, buying time for other chemo or rad to do the heavy lifting. When used as a monotherapy it is a time buyer primarily. See http://www.oralcancerfoundation.org/treatment/targeted_therapies.htm

Brian, stage 4 oral cancer survivor. OCF Founder and Director. The first responsibility of a leader is to define reality. The last is to say thank you. In between, the leader is a servant.